Immunotherapy for msi-h stomach cancer before surgery
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests how well immunotherapy (drugs that boost your immune system to fight cancer) works before surgery for stomach cancer that has a specific genetic marker (dMMR or MSI-H). It aims to find factors that predict response, which may lead to more personalized and effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with adenocarcinoma (a common type of stomach cancer) in the stomach or at the junction where the stomach meets the esophagus, specifically type II or III.
- Your tumor has a special genetic feature called dMMR or MSI-H, which may make it more responsive to immunotherapy.
- Your cancer is at a stage where it can potentially be removed by surgery, and your doctor plans for you to receive treatment before the surgery.
- You are willing to receive immunotherapy (drugs that help your immune system fight cancer), which may be combined with or without standard chemotherapy.
- You have not had any prior anti-cancer treatment for this stomach cancer (except a bypass surgery to relieve a blockage).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy medicine (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for people with a specific type of stomach cancer (MSI-H/dMMR) that can be removed by surgery. The goal is to see if this combination helps shrink the tumor and improve outcomes before surgery.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
This trial tests whether giving the immunotherapy drug sintilimab along with low-dose radiation before surgery can help shrink stomach cancer that has a specific DNA repair defect (dMMR/MSI-H). The goal is to make surgery more effective and improve outcomes.
This trial tests whether patients with advanced gastric cancer (a specific type called dMMR/MSI-H) can be treated without surgery after receiving immunotherapy and chemotherapy. The goal is to see if this approach can control the cancer while avoiding the risks of surgery.
This trial tests giving an immunotherapy drug before surgery to see if it can increase immune cells in the tumor and improve outcomes for people with advanced stomach cancer. It may help shrink the tumor and make surgery more effective.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.